GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01). Phase 1 trial of a KRAS ...
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that, following advancement of key startup ...
Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution PHILADELPHIA, ...
AC Immune received a CHF10 million upfront payment and will receive a subsequent milestone payment subject to Phase 1 dosing, in addition to other potential development, regulatory and commercial ...
Membership of the Immune Oncology (IO) Program is comprised of a diverse and multidisciplinary group of investigators with robust strength in immunogenetics, cellular and molecular immunology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results